GC

GC Cell

Yongin KRFounded 2017200 employees
Private CapbiotechPrivateOncology
Platform: NK Cell Ther
Market Cap
N/A
All Drugs
3
Clinical Trials
7
Failed / Terminated
2
FDA Approved
1
Drug Pipeline (3 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
GC-6461GC-6461Preclinical2ADCCDK4/6EZH2iCML
GC-7403GC-7403Phase 2/32Cell TherapyPI3KαWEE1iObesityGA
IvorasimodGC-3526Approved3RadioligandPD-1Anti-TauCKDPompe
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (6)
2026-01-23
Ivorasimod Ph3 Readout
Pompe
Past
2028-03-04
Ivorasimod Ph3 Readout
MDS
Ph3 Readout
2030-02-02
Ivorasimod Ph3 Readout
CKD
Ph3 Readout
2030-10-27
GC-6461 Interim
CML
Interim
2031-03-13
GC-7403 Ph3 Readout
GA
Ph3 Readout
2031-08-12
GC-6461 Interim
CML
Interim